Oncology Institute Valuation
| TOI Stock | USD 0.17 0.02 13.33% |
Oncology Institute seems to be undervalued based on Macroaxis valuation methodology. Our model determines the value of Oncology Institute from analyzing the company fundamentals such as Shares Outstanding of 75.56 M, operating margin of (0.17) %, and Return On Equity of -1.26 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Oncology Institute's valuation include:
Price Book 0.7394 | Enterprise Value 87 M | Enterprise Value Ebitda (1.87) | Price Sales 0.0317 | Enterprise Value Revenue 0.2296 |
Undervalued
Today
Please note that Oncology Institute's price fluctuation is out of control at this time. Calculation of the real value of Oncology Institute is based on 3 months time horizon. Increasing Oncology Institute's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Oncology Institute is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Oncology Stock. However, Oncology Institute's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.17 | Real 0.75 | Target 2.5 | Hype 0.15 |
The intrinsic value of Oncology Institute's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Oncology Institute's stock price.
Estimating the potential upside or downside of Oncology Institute helps investors to forecast how Oncology stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Oncology Institute more accurately as focusing exclusively on Oncology Institute's fundamentals will not take into account other important factors: When choosing an evaluation method for Oncology Institute, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Oncology Institute Cash |
|
Oncology Valuation Trend
Oncology Institute's real value analysis enables investors to forecast the earnings more efficiently. Using both Oncology Institute's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing decisions.
Oncology Institute Total Value Analysis
Oncology Institute is at this time estimated to have company total value of 87 M with market capitalization of 11.45 M, debt of 119.67 M, and cash on hands of 64.21 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Oncology Institute fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
87 M | 11.45 M | 119.67 M | 64.21 M |
Oncology Institute Investor Information
About 20.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.74. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oncology Institute has Price/Earnings (P/E) ratio of 190.67. The entity recorded a loss per share of 0.77. The firm had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from Oncology Institute's historical financial statements, Oncology Institute is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Oncology Institute Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Oncology Institute has an asset utilization ratio of 154.96 percent. This signifies that the Company is making $1.55 for each dollar of assets. An increasing asset utilization means that Oncology Institute is more efficient with each dollar of assets it utilizes for everyday operations.Oncology Institute Ownership Allocation
Oncology Institute owns a total of 75.56 Million outstanding shares. 30% of Oncology Institute outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Oncology Institute Profitability Analysis
The company reported the last year's revenue of 324.24 M. Reported Net Loss for the year was (83.07 M) with profit before taxes, overhead, and interest of 52.09 M.About Oncology Institute Valuation
An absolute valuation paradigm, as applied to Oncology Stock, attempts to find the value of Oncology Institute based on its fundamental and basic technical indicators. By analyzing Oncology Institute's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Oncology Institute's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Oncology Institute. We calculate exposure to Oncology Institute's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Oncology Institute's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 59.6 M | 45 M | |
| Pretax Profit Margin | (0.26) | (0.24) | |
| Operating Profit Margin | (0.24) | (0.25) | |
| Net Loss | (0.26) | (0.24) | |
| Gross Profit Margin | 0.18 | 0.22 |
Oncology Institute Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 73.7 M |
Oncology Institute Current Valuation Indicators
Valuation refers to the process of determining the present value of Oncology Institute and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Oncology we look at many different elements of the entity such as Oncology's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Oncology Institute, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Oncology Institute's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Oncology Institute's worth.Complementary Tools for Oncology Stock analysis
When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |